GCP Compliant Certified CROs

Global leader in providing preclinical and clinical laboratory services. Charles River offers early-stage discovery, safety assessment, and clinical support services to pharmaceutical and biotech companies worldwide.

Global provider of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. ICON specializes in clinical research with operations across 53 countries.

Formerly Covance, Labcorp Drug Development provides comprehensive drug development services from early discovery through post-approval. One of the world's largest CROs with extensive nonclinical and clinical capabilities.

A leading global contract research organization acquired by Thermo Fisher Scientific. PPD provides comprehensive clinical development services including laboratory, data management, and regulatory services.

Global biopharmaceutical services company providing clinical research, regulatory consulting, and market access services. Parexel has supported the development of many blockbuster drugs.

Integrated biopharmaceutical solutions company combining clinical development and commercial capabilities. Syneos offers end-to-end solutions from Phase I through product launch and beyond.

Japanese CRO subsidiary providing clinical monitoring, data management, and pharmacovigilance services specializing in small-to-mid-size pharma and biotech sponsors across Asia.

Kenya-founded niche full-service CRO specialising in vaccine, drug, and medical device clinical trials across sub-Saharan Africa with in-country teams in Kenya, Tanzania, Uganda, South Africa, and Ghana.

The first South African full-service CRO providing Phase I-IV clinical trial management across Southern Africa and other African regions since 2007.

Tunis-based CRO covering most African countries, offering clinical research services, WHO-certified bioequivalence studies, regulatory submissions, pharmacovigilance, and pharmaceutical training.

Buenos Aires-based full-service Latin American CRO with operations across Argentina, Chile, Uruguay, Brazil, Peru, Mexico, and Colombia, covering Phase I-IV studies.

Hyderabad-based mid-size CRO operating across India, the Philippines, Thailand, Vietnam, and the Middle East, providing Phase I-IV clinical trial services and regulatory affairs.

Melbourne-founded CRO supporting small and mid-sized biotech companies across all clinical development stages including regulatory affairs, biometrics, and manufacturing scale-up.

Belgian mid-size CRO providing clinical trial management, medical monitoring, and pharmacovigilance services across the EU with particular strength in oncology and rare disease.

Budapest-based CRO providing full-service clinical trial management across Hungary and Central Europe, with capabilities in oncology, rare disease, and biosimilar clinical programs.

Indian CRO providing Phase I BA/BE studies, bioanalytical testing, clinical pharmacology and early-phase research services with USFDA-inspected facilities in Navi Mumbai.

Clinical development and strategic resourcing organization providing full CRO services and functional service provider models to biopharma companies since 1994.

Leading IRB, IACUC, and consulting services provider for clinical and preclinical research, plus site management and performance optimization services.

Frankfurt-based specialty CRO focusing on endocrinology and oncology clinical development with strong European regulatory expertise.

US-based CRO providing full-service Phase I-IV clinical trial support for small and mid-size pharma and biotech with expertise in CNS, oncology, and infectious disease.

Mid-size global CRO under ALTEN Group formed by integrating Cmed and Larix, with deep oncology, rare disease, and cell/gene therapy clinical trial expertise across the US and Europe.

India-based integrated CDMO and CRO providing API R&D, formulation development, bioanalytical services, and Phase I-IV clinical research from facilities in Hyderabad.

Riyadh-based Saudi CRO providing clinical trial management, regulatory consulting, and pharmacovigilance services across the GCC region with SFDA regulatory expertise.

Canadian specialty CRO focused exclusively on gastrointestinal disease clinical trials with proprietary central reading and histopathology services for IBD and liver disease.

Gainesville, Florida-based dermatology and wound care CRO providing Phase I-IV clinical trials, photoprotection testing, and clinical pharmacology services for topical drug products.

Full-service CRO purpose-built for small and mid-size biotech, combining legacy of CATO Research, SMS Oncology, Pharm-Olam, and Nuventra into an integrated clinical development partner.

CDMO headquartered in Northern Ireland providing GMP API synthesis, drug product development, clinical trial supply manufacturing, and biomarker services across North America and Europe.

Mid-size CRO offering early-phase clinical studies, preclinical safety assessment, and bioanalytical services. Known for integrated PK/PD programs from preclinical through Phase I.

Full-service CRO integrating translational sciences, clinical pharmacology, bioanalysis, and regulatory strategy from preclinical through Phase IV development.

Full-service CRO based near FDA headquarters with 25+ years of regulatory and clinical trial expertise including adaptive designs, BE/BA studies, and pharmacovigilance.

Canadian bioanalytical CRO providing GLP-compliant LC-MS/MS bioanalytical services, PK analysis, and method development for pharmaceutical and biotech sponsors.

Regional full-service CRO headquartered in Riyadh providing clinical trial monitoring and pharmaceutical consultancy across Egypt, Lebanon, Jordan, Gulf States, and Saudi Arabia.

Hyderabad-headquartered integrated CRDMO providing CRO and CDMO solutions for small and large molecules to 450+ global pharma and biotech clients with 3,000+ professionals.

Full-service CRO headquartered in Bangalore supporting Phase II-IV pharmaceutical, biotechnology, and medical device trials across India.

German CRO and FSP provider delivering clinical trial management, pharmacovigilance, and medical information services across the DACH region and Central Europe.

French CRO providing Phase I-III clinical development services with particular expertise in metabolic disease, endocrinology, and cardiovascular trials across Europe.

French CRO providing Phase I-III clinical trial management and monitoring services across France and Western Europe, with expertise in rare disease and orphan drug development.

Clinical research division of India's major healthcare group, leveraging access to 30+ hospitals and diverse patient populations for multi-site Phase II-IV trials across therapeutic areas.

Nantes-based French CRO specialising in CNS, sleep medicine, and neuroscience clinical trials with proprietary EEG/PSG expertise and Phase I-II clinical pharmacology capabilities.

Phase I-III oncology CRO providing clinical trial management with deep oncology expertise for small and mid-size pharma and biotech sponsors.

Johannesburg-based South African research institute conducting large-scale TB and HIV clinical trials across multiple African sites, with capabilities in vaccine trials and epidemiological studies.

Australian full-service CRO providing Phase 1–3 clinical trial management with expertise in biotech-focused programs. Known for the Australian Clinical Trial Notification (CTN) regulatory pathway advantage.

Global CRO built exclusively for MedTech, integrating regulatory strategy, clinical development, and market access reimbursement for device and IVD programs from the Netherlands since 1988.

Clinical pharmacology and bioanalytical CRO providing Phase I studies, bioequivalence, and PK/PD studies from a purpose-built 150-bed clinical pharmacology unit in Dilworth, Minnesota.

Singapore-based specialty CRO providing preclinical pharmacology, toxicology, and early clinical development services with particular expertise in biologics and biosimilar characterization.

Latin America's first Academic Research Organisation affiliated with the Federal University of Sao Paulo, leading international multicentre studies in cardiology and infectious disease.

Dhaka-based CRO providing clinical trial management and bioequivalence studies for Bangladesh's pharmaceutical industry, one of the largest generic drug markets in South Asia.

Italian CRO providing Phase I clinical pharmacology studies including bioequivalence, food-effect, and drug interaction trials from its dedicated Phase I unit in Milan.

Osaka-based clinical CRO specializing in medical device and diagnostic clinical trials in Japan, providing regulatory consulting, site management, and data management services under PMDA guidelines.

Canadian Phase I and bioequivalence CRO with a 150-bed clinical facility in Toronto and over 2,500 completed BA/BE and early-phase studies for global pharma clients.

Indian medical imaging and cardiac safety CRO providing centralized ECG reading, imaging endpoint adjudication, and eClinical technology services for global clinical trials.

Israeli CRO specialising in clinical trial management, biostatistics, and regulatory affairs with expertise across Phase I-IV studies in oncology and rare diseases.

Lithuanian regulatory affairs consultancy providing EU regulatory strategy, marketing authorisation applications, pharmacovigilance, and medical writing across 30+ European markets.

UK-based specialist oncology CRO providing early-phase clinical trial management, tumour genomics, and biomarker-driven trial design for immuno-oncology programmes.

Nigerian contract research organisation providing clinical trial support, site management, data management, and regulatory affairs services for pharmaceutical sponsors in West Africa.

Miami-based full-service CRO specialising in complex and rare disease clinical trials with deep regulatory expertise for accelerated and breakthrough therapy designations.

Clinical research organization providing Phase I-III clinical trial management, monitoring, and regulatory services with a focus on small-to-mid-size biotech and specialty pharma sponsors.

Transatlantic Phase 1 CRO with clinical pharmacology units in Rennes (France) and Newark (NJ, USA). Specializes in first-in-human, CNS, cardiac safety, and abuse liability studies.

Buenos Aires-based CRO providing Phase II-IV clinical trial management across Argentina, with strong site networks in cardiology, endocrinology, and rheumatology.

South Korean CRO specializing in clinical trial management and data services for pharmaceutical companies developing products for both Korean and global regulatory submissions.

South Korea's first CRO founded in 1997, providing comprehensive Phase I-IV clinical development solutions including regulatory affairs, data management, pharmacovigilance and medical translation.

Regulatory affairs and clinical development consultancy providing full-service FDA/EMA submission support, pharmacovigilance, and clinical trial management for small pharma and biotech.

Independent early-phase CRO in the Netherlands specializing in first-in-human and Phase I trials using innovative biomarkers, with a purpose-built 54-bed clinical research unit adjacent to Leiden University Medical Center.

Accra-based Ghanaian CRO specializing in vaccine clinical trials and infectious disease research across West Africa, with established relationships with WHO and GAVI-funded programs.

Clinical development arm of CJ HealthCare, providing Phase I-IV clinical trial management, BA/BE studies, and regulatory support services across South Korea with access to CJ's hospital network.

Adelaide-based Phase 1 clinical pharmacology unit conducting first-in-human, bioequivalence, and biosimilar studies. Operates a 150-bed facility at the Royal Adelaide Hospital campus.

Japan's largest independent CRO providing end-to-end pharmaceutical development services including clinical operations, data management, regulatory affairs, and post-marketing surveillance across Asia.

High-performance Brazilian clinical research CRO now part of QIMA Life Sciences, specialising in bioequivalence, Phase I-III trials, and ANVISA regulatory strategy.

Nanjing-based clinical CRO and Pharmaron subsidiary providing one-stop clinical development services in China including regulatory affairs, clinical operations, pharmacovigilance, and bioanalysis.

Istanbul-based Turkish CRO offering clinical project management, site monitoring, regulatory submissions, and pharmacovigilance services across Turkey and the Balkans.

Ho Chi Minh City-based Vietnamese CRO providing Phase II-IV clinical trial management, BA/BE studies, and regulatory consulting for pharmaceutical companies entering the Vietnamese market.

Swiss independent Phase I and early-phase clinical CRO in Basel with a dedicated 24-bed clinical pharmacology unit, specializing in first-in-human studies for oncology, cardiovascular, and CNS compounds.

Full-service Australian CRO delivering clinical research services across Australia and New Zealand, supporting sponsors through Phase I-IV development.

Swedish CRO with a 12-bed first-in-human research unit at Uppsala University Hospital, specializing in Phase I and Phase II trials with approximately five FIH studies annually.

Hamburg-based academic CRO affiliated with University Medical Center Hamburg-Eppendorf, conducting Phase I-III clinical trials with particular expertise in oncology and infectious disease.

Full-service mid-size CRO specialising in rare diseases, transplantation, nephrology, and immunology across Phase I-IV trials.

China-based global CRO providing full clinical development services from Phase I through IV with strong site networks across China, Korea, and Southeast Asia.

Full-service, technology-enabled oncology-focused CRO serving biotechnology and pharmaceutical companies across all clinical phases from Wilmington, Delaware.

US-based site management organisation providing clinical trial site identification, feasibility, start-up, and monitoring services for pharma and biotech sponsors.

Specialized early clinical research CRO providing Phase I clinical pharmacology, bioanalytical, and ADME services from dedicated clinical units.

Celerion's clinical pharmacology facility in Lincoln, Nebraska, providing early-phase clinical trials, BA/BE studies, and cardiac safety testing with a 200+ bed Phase I unit.

Swiss clinical pharmacology unit specialising in first-in-human Phase I trials, PK/PD studies, and early-phase bioequivalence studies for small molecules and biologics.

Global precision medicine CRO delivering biomarker and bioanalytical services including flow cytometry, histopathology, proteomics, and genomics for clinical trials.

Santiago-based Phase I clinical pharmacology unit providing first-in-human, BA/BE, and pharmacokinetic studies for Latin American and international sponsors under ICH-GCP standards.

North America's largest integrated research organization with 40+ wholly owned clinical sites across Canada and the US, conducting Phase I-IV trials across 35+ therapeutic areas.

UK-headquartered global mid-size CRO (now part of LabCorp/Covance) with deep expertise in oncology, rare diseases, and paediatric clinical trials across 30+ countries.

Mid-size global CRO acquired by Labcorp providing clinical development services from Phase I through Phase IV with operations across Europe, Asia, and the Americas.

Thai royal research institute conducting preclinical and clinical research in oncology, environmental toxicology, and natural products with GLP-certified laboratory facilities.

Global clinical trial technology and endpoint services company providing cardiac safety (ECG), respiratory, imaging, patient-reported outcomes, and clinical event adjudication for pharma and biotech sponsors.

Europe's first specialist CRO dedicated to psychedelic compound clinical research, providing full-service trial design and execution for novel psychiatric treatments in the UK.

Ahmedabad-founded full-service CRO and one of Asia's largest BA/BE and early-phase Phase I units, offering clinical, bioanalytical and biometric services across 4 countries.

Singapore-founded full-service CRO with operations across 12 Asia-Pacific markets, offering clinical trial management, regulatory affairs and data services.

Taiwan and China-focused CRO providing clinical development, regulatory strategy, and bioanalytical services with expertise in NMPA/TFDA dual-track submissions for sponsors entering Greater China.

Global full-service CRO founded in 1995 with strong Asia-Pacific and European presence, expanded via acquisition of CROMSOURCE for deeper European clinical operations.

Glasgow-founded, India-expanded full-service CRO providing clinical trial management, site management, and regulatory services across Asia-Pacific, Europe, and North America.

Cotonou-based African CRO with a unique West, Central, and East Africa footprint providing clinical trial site management, pharmacovigilance, data management, and market research services.

Mexico City-based CRO specializing in CNS and psychiatry clinical trials across Latin America, with established investigator networks in Mexico, Colombia, and Chile.

ISO 9001-certified full-service CRO with offices in Australia, Singapore, and India providing Phase I-IV trial management across the Asia-Pacific region.

Indian CRO providing clinical data management, biostatistics, pharmacovigilance, and medical writing services for global pharmaceutical and biotech companies at competitive costs.

Delhi-based Indian CRO providing regulatory and clinical trial management services across pharma, medical devices, and nutraceuticals.

Clinical technology company providing eCOA, eConsent, and clinical data capture solutions integrated with CRO-like trial management capabilities for decentralized and hybrid clinical trials.

Australian full-service CRO focused on early-phase clinical trials in oncology, rare disease, and dermatology, leveraging Australia's Clinical Trial Notification scheme for faster trial start-up.

Bangalore-based CRO subsidiary of Biocon offering early-phase clinical trials, bioequivalence studies, bioanalytical testing and Phase II-IV services with expertise in biosimilars.

The only global full-service CRO focused exclusively on CNS drug development, with involvement in 22 FDA-approved CNS therapies across 13 indications.

New York-based Phase I CRO operating an 80-bed clinical pharmacology unit for first-in-human, CNS, cardiac safety, and abuse liability studies.

Technology-enabled mid-size clinical CRO offering Phase I-IV development services with particular strength in oncology, rare disease, and CNS therapeutic areas.

Mid-size US CRO providing full-service Phase I-IV clinical trial management with expertise in oncology, rare disease, and CNS across 50+ countries.

Pennsylvania-based dermatology and aesthetics specialty CRO providing Phase I-IV clinical trial management and site services for topical, injectable, and device-based products.

Lahore-based Pakistani CRO providing Phase II-IV clinical trial management, BA/BE studies, and pharmacovigilance services with access to Pakistan's large treatment-naive patient populations.

New Jersey-based mid-size CRO and FSP provider offering clinical operations, data management, and regulatory services across 40+ countries.

Croatian full-service CRO providing Phase I-IV clinical trial management across Central and Eastern Europe with expertise in bioequivalence studies.

Madrid-based Spanish CRO providing full-service Phase I-IV clinical trial management, medical affairs, and pharmacovigilance across Iberian and Latin American markets.

Novotech's dedicated Phase I research unit in Sydney providing first-in-human, SAD/MAD, food effect, and bioavailability studies with a 30-bed clinical pharmacology facility.

Adelaide-based Australian Phase I clinical pharmacology unit within the Royal Adelaide Hospital, conducting first-in-human, BA/BE, and cardiac safety studies with a 48-bed facility.

Specialty CRO focused exclusively on CNS clinical trials, neurocognitive endpoint assessments, and central rater training for Phase I-III neuropsychiatric studies.

Monterrey-headquartered CRO operating across Mexico, Argentina, Colombia, and Brazil with 20+ years of clinical research experience merging high-efficiency standards with academic scientific rigour.

Bucharest-based Romanian CRO providing Phase I-IV clinical trial management, medical writing, and pharmacovigilance across Eastern Europe with access to Romania's large hospital networks.

Full-service clinical CRO providing Phase I-IV development support with emphasis on bioanalytical services, clinical pharmacology, and PK/PD modeling from their Salt Lake City operations.

US-based clinical-stage CRO arm specialising in endocrinology and cortisol-modulation therapeutics with expertise in Phase I-III metabolic and CNS clinical trials.

LabCorp Drug Development centre in Basel providing central laboratory services, companion diagnostics development, and specialised clinical testing for European pharma sponsors.

Labcorp's early development and Phase 1 clinical unit operating dedicated clinical pharmacology facilities. Provides first-in-human, bioavailability/bioequivalence, and thorough QT studies.

Labcorp Drug Development's Japanese operations providing preclinical safety assessment, bioanalytical services, and clinical trial support for regulatory submissions to PMDA and other Asian regulatory agencies.

Singapore-based global CRO consulting organisation assisting clients from clinical development through commercialisation with a focus on Asia-Pacific market access.

US-based CRO specializing in rare disease and pediatric clinical trials, providing end-to-end trial management with deep expertise in orphan drug development and regulatory strategy.

Belgrade-based Serbian CRO providing clinical trial management, monitoring, and regulatory support for Phase II-IV studies across the Western Balkans region.

Full-service CRO with a dual-hub strategy across Eastern Europe and the Balkans, offering end-to-end clinical trial services for Phase I-IV studies with competitive patient recruitment timelines.

European mid-size CRO providing clinical trial monitoring, project management, and regulatory services across Europe with a model combining outsourced and insourced clinical operations.

Biostatistics-focused CRO and software company pioneering adaptive trial design, group sequential methods, and clinical trial simulation for pharma and biotech.

Indian CRO affiliated with Dabur offering preclinical drug discovery, IND-enabling studies, and non-clinical research services from facilities near Delhi.

Australia's original full-service CRO since 1987, managing clinical research across all phases and most therapeutic areas for pharma, biotech and medical device companies.

Chinese CRO-turned-biotech providing clinical development services with deep oncology expertise, operating a portfolio of discovery through Phase III programs in solid tumors and hematological malignancies.

Turkish-German CRO providing Phase I-III clinical trial management, biostatistics, and regulatory consulting with focus on bridging European and Turkish markets.

South Korean full-service CRO providing clinical development services from Phase I through post-marketing with bioanalytical capabilities and strong ties to Korean academic medical centers.

South Korea's largest clinical CRO and Tigermed subsidiary, delivering full-scope clinical services with 1,200+ successful projects across pharmaceuticals, biotech, and medical devices.

Japanese CRO group providing clinical development, data management, biostatistics, and regulatory affairs services across Japan, China, Korea, and Southeast Asia.

French preclinical CRO based in Lyon evaluating efficacy and safety of new compounds including drugs, biologics, and medical devices across innovative in-vitro and in-vivo models.

Melbourne-based CRO specializing in Phase I-IIa first-in-human studies, offering rapid trial startup under Australia's CTN scheme with access to leading Australian clinical pharmacology units.

Contract research organization specializing in clinical research support for US government agencies including NIH, providing data management, biostatistics, and clinical operations for federally funded trials.

Global tech-enabled full-service CRO with strength in government-sponsored trials, infectious disease, vaccines, ophthalmology, and rare disease clinical development.

Global full-service CRO specializing in oncology, rare disease, and complex clinical trials across all development phases, with 2,900+ clinical research professionals operating in 100+ countries.

Clinical research division of Brazil's largest national pharmaceutical company, conducting Phase I-IV clinical trials across 10+ Brazilian sites with particular expertise in generics and biosimilars.

Hamburg-based dermatology specialty CRO established in 1992, providing regulatory consulting and Phase I-IV clinical trial management for pharmaceutical, device, and cosmetic dermatology products.

Lisbon-based CRO providing clinical trial management, regulatory affairs, and medical writing services across Iberia and Latin America, with particular expertise in medical devices and diagnostics.

Global real-world evidence and outcomes research firm providing observational studies, health economics, market access, and regulatory evidence generation for pharma and biotech.

Paris-based European CRO providing clinical operations, pharmacovigilance, and regulatory affairs services across 40+ countries with particular strength in oncology and rare disease.

Munich-based specialty CRO focused on medical device and in vitro diagnostic clinical studies, providing regulatory consulting, study monitoring, and clinical evaluation reports across Europe.

Texas-based Phase I clinical research unit specialising in early-phase, first-in-human, and healthy volunteer studies with integrated bioanalytical capabilities.

Contract research organization spun off from Labcorp in 2023. Provides Phase 1–4 clinical development services, patient access solutions, and regulatory consulting globally.

Clinical trial arm of Frontage Laboratories providing Phase I-III services with integrated bioanalytical capabilities, bridging bioanalytical strength with full clinical execution.

Israel's leading full-service CRO and clinical research training centre delivering clinical trial management solutions across pharmaceutical, device, and biotech sectors.

Shanghai-based specialised clinical CRO providing full clinical development services in China and APAC with expertise in navigating NMPA regulatory pathways for multinational pharmaceutical companies.

Hyderabad-based Indian CRO providing contract research in discovery chemistry, biology, DMPK, and clinical development with integrated data analytics platform GOSTAR.

Indian research services company providing medicinal chemistry, computational chemistry, biology, DMPK, and clinical development services for global pharma and biotech companies.

Asia-Pacific focused full-service CRO providing clinical trial management, data management, and biostatistics services with particular expertise in cardiovascular, renal, and diabetes trials.

German regulatory affairs consultancy providing EU regulatory strategy, marketing authorisation applications, and scientific advice for pharmaceutical and biotech sponsors.

Academic CRO based at Griffith University on the Gold Coast, conducting clinical trials in metabolic disease, sports medicine, and natural health products under TGA regulatory framework.

Mexico City-based CRO and leading provider of decentralised clinical trial home visit services, patient recruitment, and community research site networks across 22 Latin American countries.

Life science regulatory and clinical development consultancy specialising in regulatory strategy, quality management, and organisational support for biotech and pharma.

London-based early phase CRO conducting Phase 1 healthy volunteer and patient studies. Operates a dedicated clinical pharmacology unit at the Cumberland Business Park with 100+ bed capacity.

Chinese pharmaceutical company providing contract research and clinical development services for pharmaceutical companies seeking NMPA approvals in China.

Munich-based mid-size CRO providing Phase I-IV clinical trial management, regulatory consulting, pharmacovigilance, and medical affairs across Europe and Asia.

Phase I clinical research unit in New Jersey providing first-in-human, food effect, bioequivalence, and early-phase pharmacokinetic studies for pharmaceutical sponsors.

Bogota-based Colombian CRO providing clinical trial management, regulatory affairs, and pharmacovigilance services across the Andean region including Colombia, Peru, and Ecuador.

ICON's Australian operations leveraging Australia's CTN scheme for rapid Phase I trial initiation, supporting multinational sponsors with early-phase development in the APAC region.

Netherlands-based bioanalytical centre of excellence providing large-molecule bioanalysis, immunogenicity, and cell-based assay services for biologics and biosimilar programmes.

ICON's dedicated bioanalytical division providing GLP-compliant small and large molecule bioanalysis, immunogenicity testing, and biomarker analysis from state-of-the-art laboratories.

Specialised bioanalytical laboratory in New York providing large-molecule bioanalysis, immunogenicity testing, and ligand-binding assay development for biologics programmes.

ICON's dedicated early development division operating clinical pharmacology units in the US and Europe, conducting first-in-human, PK/PD, food effect, and drug interaction studies.

ICON's Japanese operations providing full-service clinical development for pharmaceutical companies conducting trials in Japan and supporting PMDA regulatory submissions.

Global clinical research and health data analytics company formed from the merger of IMS Health and Quintiles. Offers end-to-end clinical development, real-world evidence, and technology solutions.

IQVIA's Indian operations providing comprehensive clinical development, regulatory consulting, and healthcare analytics services for pharmaceutical companies across South Asia.

IQVIA's Japanese subsidiary providing clinical operations, real-world data analytics, regulatory strategy and technology solutions with one of the largest clinical operations teams in Japan.

UAE's CRO headquartered under M42 Abu Dhabi, specialising in real-world evidence and comprehensive clinical trials across all therapeutic domains in the Gulf region.

Clinical research division of South Korea's Ildong Pharmaceutical group, conducting domestic and international Phase I-IV studies with access to major Korean academic medical centres.

Retina-specialty CRO with offices across Latin America, Asia, and Australia supporting clinical trials in 18+ countries for ophthalmic and rare disease indications.

Indian full-service CRO with offices in India, USA, UAE, and Hungary delivering Phases I-IV trials and real-world evidence studies across 18+ therapeutic areas.

Clinical operations arm of the former inVentiv Health (now Syneos Health) providing Phase I-IV trial management with particular expertise in dermatology and CNS therapeutic areas.

World-leading ophthalmology-specialized CRO conducting preclinical and clinical research from ocular surface to posterior segment, with 70+ ocular drugs and devices brought to market.

Canadian CRO providing Phase II-IV clinical trial management, real-world evidence studies, and health economics consulting with 30+ years of experience in respiratory, rheumatology, and dermatology.

Therapeutically specialized CRO focused on CNS, cardio-metabolic, renal, and rare disease trials, providing end-to-end CRO and SMO services across 39 countries with 220,000+ subjects enrolled.

Kobe-based Japanese CRO and research institute specializing in preclinical safety assessment, pharmacology and drug metabolism studies with GLP-accredited facilities.

Full-service CRO based in Warsaw providing Phase I-IV clinical trial management, regulatory affairs, site management, and biometrics across Central and Eastern Europe.

US-Korea bridge CRO providing early-phase clinical and regulatory services tailored for Korean life science companies entering the US FDA pathway.

Kenya Medical Research Institute's clinical trials unit conducting Phase I-III vaccine, malaria, HIV, and TB studies across multiple Kenyan sites in partnership with global funders.

Canadian full-service CRO specialising in clinical trials and regulatory support for nutraceutical, cannabis, and natural health product industries.

Cincinnati-based full-service CRO providing Phase I-IV clinical trial management, clinical pharmacology, and regulatory consulting services for pharmaceutical and biotech sponsors worldwide.

Istanbul-based Turkish CRO offering Phase I-IV clinical trials, bioequivalence studies, medical device trials, and electronic data capture services.

South Korean CRO providing Phase I-IV clinical development, bioanalytical services, and regulatory consulting with particular expertise in simultaneous MFDS-FDA-EMA regulatory submissions.

Seoul-based full-service Korean CRO with 400 clinical trial experts and experience across 1,600+ studies including 180+ global multi-center trials.

Stockholm-based Nordic CRO providing clinical trial management, biostatistics, and regulatory support for Phase I-IV studies across Scandinavian countries with EMA and FDA regulatory experience.

Indian clinical CRO providing Phase I-IV clinical trials, bioanalytical services, and clinical pharmacology studies with dedicated Phase I units and bioanalytical laboratories.

Spanish full-service CRO and site management organization providing clinical trial management, regulatory affairs, and pharmacovigilance services in Spain, Italy, and Portugal.

Next-generation decentralized CRO from London using a proprietary clinical trial platform to deliver faster, more efficient trials in cardiovascular, oncology, and ophthalmology.

Perth-based clinical trial site and CRO specializing in Phase 1–3 studies across multiple therapeutic areas. Located at the Harry Perkins Institute of Medical Research.

Japanese full-service CRO with global operations providing clinical development from early phase through post-marketing with deep oncology and CNS expertise across Asia, Europe, and the US.

Global CRO with nearly 1,000 employees covering 30+ countries, providing full-spectrum multilingual clinical development from early phase through post-approval in oncology and CNS.

Phase I-III CRO and integrated research site network specialising in CNS, pain, obesity, and metabolic disease with wholly-owned clinical units in California.

Bangalore-based Indian CRO offering Phase I bioequivalence, bioanalytical and early-phase clinical research services for domestic and international generic pharmaceutical companies.

French clinical-stage gene therapy company and CRO specializing in CNS gene therapy development, providing clinical trial management for rare neurological diseases.

Japanese digital health and clinical research subsidiary of M3 Inc., leveraging its physician panel of 300,000+ doctors for clinical trial site identification and recruitment in Japan.

One of Europe's largest full-service CROs with a dedicated network of research sites across the UK, conducting global clinical studies from Phase I through Phase IV with particular strength in patient recruitment.

UK-based Phase I-IV site network and CRO operating multiple dedicated clinical research centres across Northern England for healthy volunteer and patient population studies.

Leading MEA and Pakistan CRO with 140+ employees that has conducted 300+ clinical trials in 35 countries spanning the Middle East, Africa, Pakistan, and the Eurasian Economic Union.

Full-service Indian CRO backed by the Manipal Group, offering end-to-end clinical development services from Phase I through Phase IV with particular expertise in BA/BE studies and oncology trials.

Vietnam's dedicated CRO/SMO founded by Japan's SRD Group, applying Japanese GCP expertise to support clinical trials at Vietnamese research hospitals.

Dhaka-based clinical data management and biostatistics CRO providing remote monitoring, data entry, and statistical analysis services for global pharmaceutical clinical trials.

Oncology CRO founded by oncology thought-leaders specializing in Phase I and II immuno-oncology trials in North America and Europe.

Australian not-for-profit pharmaceutical company developing and registering medicines for neglected tropical diseases, providing regulatory and clinical development services for global health products.

Pioneer Japanese CRO founded in 1982 providing one-stop pharmaceutical development services from early-phase through post-marketing activities in Japan and Asia.

Scientifically-driven, global, full-service clinical CRO providing Phase I-IV clinical development services. Medpace is known for its therapeutic expertise and operational efficiency.

Specialist CDMO for cell and gene therapy products offering GMP clinical and commercial manufacturing and development solutions for ATMPs from German, US, and Japanese facilities.

Australian boutique CRO specialising in early-phase and first-in-human MedTech clinical trials across Australia, New Zealand, and the USA.

Ankara-based Turkish CRO specialising in bioequivalence and bioavailability study management, clinical operations, data management, and medical writing for multinational sponsors.

US-India hybrid CRO providing clinical trial management, regulatory affairs, pharmacovigilance, and medical writing with cost-effective offshore delivery from India.

Full-continuum preclinical CRO providing integrated in vitro and in vivo services including efficacy, toxicity, biodistribution, and product release studies in small and large animals.

Danish biomarker CRO specializing in neoepitope biomarker technologies for tissue remodeling, conducting clinical trials in rheumatology, musculoskeletal, and metabolic disease with CAP-accredited laboratories.

Israel-based CRO with deep expertise in the Israeli pharmaceutical, medical device, and healthcare industry delivering clinical trial management for international sponsors.

Mid-size CRO acquired by IQVIA providing boutique-level clinical development services with deep therapeutic expertise in oncology, CNS, and rare disease for small-to-mid-size biotech sponsors.

Asia-Pacific specialist CRO providing full-service clinical development capabilities with deep expertise in the Asia-Pacific regulatory landscape.

Greater China operations of Australian CRO Novotech, providing full-service clinical trial management across mainland China, Hong Kong and Taiwan with NMPA submission expertise.

Malaysian office of Novotech, Asia-Pacific's largest CRO, providing clinical trial management, regulatory affairs, and site management for Phase I-IV studies across Malaysia and ASEAN markets.

Leading Australian Phase 1 clinical trials unit operating in Melbourne, Brisbane, and Minneapolis. Specializes in first-in-human, oncology Phase 1, and healthy volunteer studies with rapid enrollment timelines.

US arm of Australian CRO Nucleus Network, operating early phase clinical trials from their Minneapolis facility. Provides Phase 1 studies with access to diverse patient populations.

Clinical pharmacology consulting firm specializing in PK/PD modeling, dose optimization, biosimilar development strategy, and regulatory science for pharmaceutical and biotech companies.

Fully integrated German CRO/CDMO offering drug discovery, non-clinical studies, pharmaceutical analysis, GMP manufacturing, and early-phase clinical trials from facilities in Germany and France.

Germany-based mid-size CRO providing early-phase clinical trials (Phase I/IIa), bioanalysis, DMPK, and translational medicine services from facilities in Neu-Ulm and Berlin.

Nuvisan's Integrated Contract Bioscience facility in Neu-Ulm, Germany, providing preclinical ADME, bioanalysis, and Phase I clinical trials with a 120-bed clinical pharmacology unit.

Eastern and Central European CRO founded in 2005, providing Phase I-IV and bioequivalence services in oncology and infectious disease across 20+ countries.

Milan-based Italian CRO providing clinical trial management, monitoring, and pharmacovigilance services across Southern Europe with expertise in medical devices and dermatology trials.

Regulatory consulting firm providing IND/NDA/BLA submission strategy, CMC consulting, and FDA interaction management for biotech and pharmaceutical sponsors.

The first CRO established in Turkey, providing clinical and epidemiological research management to national and international pharmaceutical companies since 1997.

New Zealand's leading late-phase clinical research organisation delivering Phase III-IV trial results at speed and scale for global sponsors.

Leading Central and Eastern European full-service CRO operating across 30+ countries with 510+ staff and 1,700+ completed studies, expanded through acquisitions of Crown CRO, SSS International, and MKS Research.

World's leading ophthalmology-specialized CRO providing full-service clinical development from Phase I through Phase IV exclusively for ophthalmic therapeutics, devices, and surgical products.

Independent New Zealand clinical research company conducting Phase I-IV trials with specialist early-phase capabilities and access to New Zealand's rapid ethics approval system.

Belgium-based specialty CRO focused on epidemiology and vaccine development with local hubs in South Africa, Ghana, Kenya, and Morocco, having conducted 500+ studies in 20+ African countries.

Full-service CRO headquartered in Dubai covering 31 countries across the Middle East and Africa with clinical operations, regulatory affairs, pharmacovigilance, and data management services.

Global CRO acquired by ICON in 2021. Provides full-service clinical development, data management, and strategic consulting across all major therapeutic areas.

Cambridge-based specialty CRO focused on biostatistics, statistical programming, clinical data management, and regulatory submission support for pharma and biotech.

Swiss full-service CRO operating in 56 countries with 3,000 staff, specializing in pivotal Phase II-III clinical trials in oncology, hematology, multiple sclerosis, and rare diseases.

Central European CRO headquartered in Prague providing full-service Phase I-IV clinical trial management across the Czech Republic, Slovakia, Poland, and Hungary.

Jakarta-based Indonesian CRO and bioanalytical laboratory providing BA/BE studies, clinical trials, and analytical services for pharmaceutical companies seeking Indonesian regulatory approval.

European full-service CRO formed by the 2024 merger of palleos healthcare and OCT Clinical, covering Western and Eastern Europe across 29 therapeutic areas from Wiesbaden, Germany.

European CRO providing preclinical contract research services including in vivo pharmacology, toxicology, and bioanalytical testing from GLP-certified European facilities.

Australian pharmaceutical research company providing preclinical and clinical development services with expertise in inflammatory bowel disease and gastrointestinal therapeutic areas.

Parexel's Indian operations providing clinical trial management, data management, biostatistics, and regulatory consulting for pharmaceutical companies conducting trials in India and South Asia.

Parexel's Japanese arm offering full-service clinical development, regulatory consulting and market access services with deep PMDA submission expertise.

Regulatory affairs and medical writing CRO providing IND/NDA/BLA preparation, regulatory strategy, and clinical documentation support for pharmaceutical and biotech companies.

Clinical data management and biometrics CRO specializing in biostatistics, statistical programming, and data management for small to mid-size pharmaceutical and biotech companies.

Mid-size full-service global CRO offering Phase I-IV clinical trial management with strong coverage across emerging markets in Africa, Latin America, and Eastern Europe.

Danish CRO focused on Scandinavian and Nordic clinical trial management, site selection, and regulatory submissions for pharma and medical device sponsors.

Canadian full-service CRO providing clinical research services from Phase I through Phase IV with particular expertise in bioequivalence studies and pharmacokinetic trials.

Taipei-based drug development company and CRO specializing in oncology, running Phase I-III clinical trials for new cancer therapies and out-licensing proprietary pipeline assets.

Australian CRO helping global pharma and biotech leverage the regulatory and cost advantages of clinical trials in Australia and New Zealand.

PPD's Chinese clinical operations providing Phase I-IV clinical development, regulatory strategy, and site management for multinational and domestic pharmaceutical companies in Greater China.

European regulatory affairs and pharmacovigilance services provider offering end-to-end regulatory strategy, submission management, and post-authorization compliance for pharma and biotech companies.

Award-winning specialist biometrics CRO headquartered in London, providing biostatistics, statistical programming, data management, and analytics to global pharma, biotech, and device companies.

French mid-size CRO specialising in Phase I-III clinical trials, biostatistics, and regulatory affairs with offices in Paris and North Africa.

Clinical research site in Phoenix conducting Phase I-IV clinical trials with particular strength in CNS, pain, and metabolic disease studies with rapid enrollment capabilities.

Specialty CRO focused on oncology and rare disease with 2,000+ professionals, known for biomarker-driven trial design, companion diagnostics, and translational research services.

Full-service global CRO providing clinical development services across all phases with deep expertise in CNS, rare disease, and cardiovascular therapeutic areas and strong site networks.

Multi-site clinical research organization conducting Phase I-IV trials with a network of dedicated research sites across the upper Midwest specializing in diverse therapeutic areas.

Global regulatory consulting, pharmacovigilance, and clinical research organization providing single-source regulatory strategy, compliance, and medical information services.

Specialty CRO focused on cardiometabolic clinical trials. Operates Phase 1–2 studies for obesity, diabetes, NASH/MASH, and cardiovascular endpoints with proprietary biomarker platforms.

California-based clinical CRO providing Phase I-III trial management, monitoring, and project oversight for emerging biotech and small pharma sponsors.

Bangalore-based Indian CRO specialising in Phase I-IV clinical trials, bioequivalence studies, and regulatory affairs for domestic and international pharmaceutical companies.

Brisbane-based Phase 1 clinical trial unit specializing in first-in-human, pharmacokinetic, and vaccine studies. Operates a dedicated clinical pharmacology unit at QIMR Berghofer campus.

Privately owned Israeli CRO providing clinical trial services for pharmaceutical and medical device companies targeting the Israeli market.

Global CRO providing bioanalytical, clinical pharmacology, and Phase I-IV clinical trial services. QPS operates CLIA-certified bioanalytical laboratories supporting regulated studies.

One of the world's largest data-focused biometrics CROs, providing biostatistics, statistical programming, clinical data management, and medical writing without conducting clinical operations.

Translational pharmaceutics CRO integrating drug substance, drug product, and clinical testing in a single facility. Specializes in formulation development with integrated Phase 1 studies.

Translational pharmaceutics CRO/CDMO uniquely combining formulation development and clinical pharmacology under one roof, accelerating drug development timelines by running formulation and clinical testing simultaneously.

Regional full-service CRO established in Egypt conducting international clinical trials, real-world evidence, and health economic studies across the Middle East and North Africa.

MedTech CRO formed by the 2020 merger of Regulatory and Quality Solutions and Maetrics, delivering 40+ years of medical device regulatory, clinical, laboratory, and reimbursement expertise.

Philippine government research institute conducting clinical trials in tropical and infectious diseases including dengue, TB, and malaria, serving as a WHO-recognized reference laboratory.

Oklahoma-based early-phase clinical research site specialising in Phase I healthy volunteer studies, PK/PD trials, and bioequivalence studies.

Full-service CRO founded on biostatistics and data science excellence, supporting Phase I-IV trials across rare disease, immunology, and ophthalmology from Research Triangle Park.

Full-service contract research and consulting organization providing clinical trial management, biostatistics, data management, and regulatory services with particular expertise in rare disease and pediatrics.

Full-service CRO providing clinical research, biostatistics, data management, and regulatory services with particular expertise in ophthalmology, CNS, and rare disease.

London-based Phase 1 clinical research unit specializing in early phase clinical trials, pharmacokinetics, and healthy volunteer studies. Located at Guy's Hospital campus.

National clinical research coordinating body in Singapore established by A*STAR and MOH, offering study design, project management, data management, and biostatistics to pharma and academic sponsors.

India's original CRO founded in 1996 providing clinical trial operations, FSP services, data management, medical writing, biostatistics and pharmacovigilance across global programs.

Vietnam's first locally established and Ministry of Health-approved CRO providing clinical trial management and site support across Vietnamese hospitals.

Japan's pioneering CRO founded in 1957 offering non-clinical safety evaluation including NHP studies, clinical Phase I-IV development, and a proprietary nasal drug delivery platform.

Japanese CRO established in 1989 offering full CRO and SMO services in Japan and Vietnam through its Asia Clinical Trial Support Alliance network.

Slovak-founded global full-service CRO with integrated clinical supply chain and depot network spanning Europe, North America, LATAM, APAC, and South Africa.

Nairobi-based East African CRO providing Phase II-III clinical trial management and site coordination for infectious disease, vaccine, and maternal health studies across Kenya, Uganda, and Tanzania.

ISO 9001-certified Nigerian CRO with offices in Lagos and Nairobi specialising in Phase III-IV clinical trials, pharmacovigilance, and regulatory affairs across Africa.